Discover how the Flamma Group transformed advanced pharmaceutical manufacturing by implementing a state-of-the-art continuous manufacturing plant. This cutting-edge facility meets the stringent requirements of cGMP and ATEX standards. This incorporates the latest in modular synthesis technology to achieve safer, more efficient, and sustainable production of pharmaceutical intermediates.
By submitting your information, you’re giving us permission to email you. You may unsubscribe at any time. We do not sell your data.
Flamma Group, in collaboration with Microinnova Engineering, has revolutionized pharmaceutical production with a state-of-the-art continuous manufacturing plant. This facility, fully compliant with cGMP and ATEX standards, integrates advanced modular synthesis technology to enhance efficiency, safety, and sustainability in pharmaceutical intermediate production.
The plant features three stainless steel liquid dosing lines, each designed for a flow rate of 80 to 1500 ml/min. These lines feed into the Corning® G4 reactor. There the primary reaction and subsequent quenching take place under precisely controlled conditions. Dual thermostats enable different temperature levels at various process stages, optimizing reaction performance.
The partly modular design of the reactor system allows for enhanced flexibility, enabling the use of different reactor modules to accommodate a variety of reaction conditions. This innovation, combined with process intensification and flow chemistry, has yielded remarkable results:
Microinnova’s engineers are available to provide turnkey solutions or retrofits to improve safety, capacity, and sustainability in existing production systems. The successful collaboration with Flamma Group has resulted in a high-performance, future-ready manufacturing plant, setting a new benchmark in pharmaceutical synthesis.
Download the full case study to explore the technical innovations and sustainable impact driving this transformation.